DB18923InvestigationalProtein Based Therapies
Ertumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy).
- Mechanism
- Curator reviewed
Pharmacologically active on T-cell surface glycoprotein CD3 epsilon chain and Receptor tyrosine-protein kinase erbB-2
- Also known as
- Anti-cd3 x anti-her-2-neu bispecific monoclonal antibody
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Ertumaxomab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account